| Literature DB >> 30153853 |
José Andrés González Coraspe1, Joachim Weis1, Mary E Anderson2, Ute Münchberg3, Kristina Lorenz3, Stephan Buchkremer1, Stephanie Carr4, René Peiman Zahedi3,5,6, Eva Brauers1, Hannah Michels4, Yoshihide Sunada7, Hanns Lochmüller4,8,9,10, Kevin P Campbell2, Erik Freier3, Denisa Hathazi3, Andreas Roos11.
Abstract
BACKGROUND: Caveolin-3 (CAV3) is a muscle-specific protein localized to the sarcolemma. It was suggested that CAV3 is involved in the connection between the extracellular matrix (ECM) and the cytoskeleton. Caveolinopathies often go along with increased CK levels indicative of sarcolemmal damage. So far, more than 40 dominant pathogenic mutations have been described leading to several phenotypes many of which are associated with a mis-localization of the mutant protein to the Golgi. Golgi retention and endoplasmic reticulum (ER) stress has been demonstrated for the CAV3 p.P104L mutation, but further downstream pathophysiological consequences remained elusive so far.Entities:
Keywords: Caveolin-3; Caveolinopathy; Chaperonopathy; LGMD1C; Protein aggregate; Skeletal muscle proteomics
Mesh:
Substances:
Year: 2018 PMID: 30153853 PMCID: PMC6114045 DOI: 10.1186/s13395-018-0173-y
Source DB: PubMed Journal: Skelet Muscle ISSN: 2044-5040 Impact factor: 4.912
Fig. 1Muscle caveolinopathies are caused by mutations of the CAV3 gene. a Subcellular localization of CAV3: the wild-type CAV3 protein localizes to the sarcolemma where it associates with components of the dystrophin-associated glycoprotein complex. CAV3 interacts directly with β-dystroglycan, nNOS and dysferlin. Moreover, CAV3 indirectly interacts with F-actin, syntrophin, dystrobrevin and laminin-2 as well as further components of the complex such as sarcoglycans and integrins. b Localization and distribution of paradigmatic CAV3 missense mutations leading to skeletal muscle phenotypes. The p.P104L mutant CAV3 protein is causative for Limb Girdle Muscular Dystrophy type 1 C. c Under physiological conditions, CAV3 is synthesized in the ER and transported through the Golgi to the sarcolemma. The missense mutant CAV3 proteins (hexagons in this carton) accumulate in the Golgi and cause ER stress and UPR activation
Fig. 2The CAV3 p.P104L mutation causes muscle pathology and influences protein stability. (a) Macroscopic comparison of hind limbs at 26 weeks wildtype mouse and a CAV3 (p.P104L) transgenic mouse reveals a moderate decline in muscle mass in the transgenic mouse which more pronounced at 52 weeks. (b) H&E staining reveals a largely normal appearance of wildtype quadriceps muscle at age 26 weeks compared to the quadriceps muscle of a transgenic animal presenting with muscle fiber caliber variability and internalized muscle fiber nuclei (Paraffin sections) (c) Transcript studies of Cav3 in quadriceps muscle of 26 weeks old p.P104L CAV3 mutant animals and wildtype littermates revealed increased cDNA abundance p.P104L CAV3 mutants. (d) Immunoblot of quadriceps muscle protein extracts (8 and 26 weeks old animals) revealing a prominent statistically significant CAV3 decrease in the mutant muscle. Coomassie blue staining was used as loading control
Fig. 3Expression of p.P104L missense mutant CAV3 disturbs ER-Golgi integrity. (a) EM findings in p.P104L CAV3 mutant quadriceps muscle: subsarcolemmal accumulation of vesicular structures (most likely corresponding to abnormal caveolae) (black arrows in 3A.1 and 3A.2) and dispersed ERGIC-Golgi structures (black arrows in 3A.3 – 3A.5). (b) Immunohistochemical studies focusing on ER-Golgi stress confirm GM130 increase. (c) Immunofluorescence studies focusing on Golgi-structure in 6 month and 1 year old animals (visualization via golgin-97 staining) revealed a statistically significant dispersion on p.P104L CAV3 transgenic animals
Fig. 4Study of ER-Golgi relevant proteins. (a) Immunohistochemical studies focusing on ER-Golgi stress confirm UPR activation (increased abundance of the phosphorylated (activated) form of eIF2α, of HSP70 and RCN2) in p.P104L muscle fibres. Interestingly, the cytosolic chaperone HSP70 shows enrichment at the sub-sarcolemmal sarcoplasm of muscle fibres expressing the mutant protein. RCN2 is accumulating in damaged muscle fibres. (b) Pathomorphological findings highlighted in Figure 3 are accompanied by reduced expression of ATL1, a protein important for the structural maintenance of the ER-Golgi system as well as altered abundance of proteins controlled by ER-stress and UPR (SIL1 and BiP, HSP70, RCN2 and SEC61). Coomassie brilliant blue staining: loading control
Fig. 5Proteomic studies to unravel the molecular nature of p.P104L induced muscular dystrophy in mice. a Proteomic workflow applied in this study. b Results of our label-free shotgun proteomic profiling are shown as a volcano plot. All points (each one represents a protein) over the horizontal line have a statistically significant p-ANOVA of ≤ 0.05. In total, 43 proteins are decreased (red points) and 77 proteins are increased in abundance (green points) in mutant mouse muscle. c Results of an in silico pathway analysis of proteins altered in abundance confirm alterations of the protein processing machinery, vulnerability of mitochondria as well as altered in ECM protein processing and cellular metabolism. In addition, there is evidence of oxidative stress and sarcolemmal vulnerability
Fig. 6Activation of proteolysis and protein aggregation in p.P104L caveolinopathy. A Immunoblot studies confirming the increased abundance of CAPN2 identified in the proteome profile and showing increased abundance of ubiquitinated proteins as well as of LC3. Coomassie brilliant blue was used as loading control. B Increased abundance of CAPN2 was confirmed via immunohistochemical studies which also revealed elevated level of SERPINE (a protein functioning as a protease) at the sub-sarcolemmal region. C EM showing autophagic vacuoles containing electron-dense myelin-like structures (6C.1–6C.7) in quadriceps muscles of animals with advanced myopathy as well as damaged, probably degenerating mitochondria (6C.8–6C.10). D CARS (two photon) microscopy confirms the presence of sarcoplasmic and sub-sarcolemmal protein-dense structures in quadriceps muscle fibres of p.P104 CAV3 transgenic animals (red fluorescent dots) but not in control muscles from wild-type littermates. Concomitant second harmonic generation signals (green fluorescent dots) corresponding to organized molecular structures such as composed myosin and myelin also indicate the presence of small abnormal build-up of organized structures within the sarcoplasm of quadriceps muscle fibres of diseased animals frequently overlapping with the protein aggregates identified by two photon microscopy. Comparative analyses and quantification of aggregates in younger and older animals revealed that aggregate-build-up coincides with disease progression. E Immunoprecipitation of ubiquitinated and p62-binding proteins with subsequent mass spectrometry-based identification towards the molecular characterization of the protein aggregates detected via electron and CARS microscopy. Data intersection revealed similar alteration of 15 proteins
Fig. 7DGC components are substrates of the impaired protein processing machinery in p.P104L caveolinopathy. A Immunoblots of paradigmatic components of the DGC confirm the proteomic findings by showing increased protein abundance of dystrophin, dysferlin, α- and β-dystroglycan, α-1-syntrophin as well as α-, β- and δ-sarcoglycan. Protein phosphatase 2AAA, stable in our proteome profile, has been used as loading control, and shows stable levels, in line with our proteomic findings. B Increased abundance of DGC components was also confirmed by immunohistochenistry focusing on δ-sarcoglycan as a paradigmatic example. Interestingly, apart from occasional sarcoplasmic deposits (black arrows in 7B.4), an enrichment in the sub-sarcolemmal region could be identified (7B.2 and 7B.3). C Immunofluorescence-based co-localization studies showing (irregular) sarcoplasmic dots immunoreactive for GRP170 (a co-chaperon of the SIL1-BiP machinery) and dysferlin. D Immunoblot analysis utilizing the monoclonal antibody IIH6, which recognizes specifically glycosylated α-dystroglycan (left panel) and the polyclonal antibody AF6868, which recognizes both α- and β-dystroglycan (right panel)